Neuropsychiatric Disease and Treatment (Jun 2021)
Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
Abstract
Pedro Such,1 José Manuel Olivares,2 Lizbeth Arias,1 Mette Troels Berg,1 Jessica Madera3 1Medical Strategy and Communication, H. Lundbeck A/S, Valby, 2500, Denmark; 2Department of Psychiatry, Hospital Álvaro Cunqueiro, Health Research Institute Galicia Sur (IISGS), CIBERSAM, Vigo, Spain; 3Global Medical Affairs, Otsuka Pharmaceutical Development & Commercialization, Inc, Princeton, New Jersey, 08540, USACorrespondence: Pedro SuchMedical Strategy and Communication, H. Lundbeck A/S, Ottiliavej 9, Valby, 2500, DenmarkTel +45 3630 1311Email [email protected]: To obtain real-world evidence of functional improvements during atypical long-acting injectable (aLAI) therapy in recent-onset schizophrenia, an online survey was conducted to assess the impact of aripiprazole once-monthly injectable 400 mg (AOM 400; partial D2 receptor agonist) and paliperidone palmitate once-monthly (PP1M; injectable, full D2 receptor antagonist).Methods: Psychiatrists provided data for their 2 most recent AOM 400 patients, 2 most recent PP1M patients. Survey included 2000 patient cases (1000 AOM 400; 1000 PP1M). Eligible patients were aged 18– 35 years, had been diagnosed with schizophrenia within 5 years, received AOM 400 or PP1M continuously for ≥ 6 months according to approved labels (mean durations: 1.6 and 1.7 years with AOM 400 and PP1M, respectively). Assessments included Global Assessment of Functioning (GAF) Scale, Personal and Social Performance Scale, Positive and Negative Syndrome Scale, and Quality of Life Scale. GAF assessments were done retrospectively and also at the time of survey.Results: Baseline mean GAF scores were 43.3 and 43.8 for AOM 400 and PP1M, respectively, indicating serious symptoms/functional impairment in both groups. Mean improvements following AOM 400 and PP1M therapy were 19.7 and 16.3 points, respectively (final scores in mild functional impairment category). Other measures assessing symptoms/functionality/quality of life demonstrated the benefits of long-term aLAI therapy.Conclusion: Schizophrenia patients with serious functional impairment prior to current aLAI treatment showed improvements in functional outcome after AOM 400 or PP1M therapy. These results suggest functional improvements with aLAIs are apparent not only in research but also real-world settings.Keywords: antipsychotic treatment, aripiprazole, aripiprazole once-monthly injectable, AOM, long-acting injectable, paliperidone palmitate once-monthly injectable
